Publicacións nas que colabora con Jordi Sierra Gil (53)

2022

  1. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

    Blood, Vol. 140, Núm. 11, pp. 1200-1228

2018

  1. CD34 + Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome 

    Biology of Blood and Marrow Transplantation, Vol. 24, Núm. 5, pp. 964-972

  2. CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis

    PLoS ONE, Vol. 13, Núm. 6

  3. Focal adhesion genes refine the intermediate-risk cytogenetic classification of acute myeloid leukemia

    Cancers, Vol. 10, Núm. 11

  4. Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting

    Medical Oncology, Vol. 35, Núm. 6

2017

  1. NEDD 9 an independent good prognostic factor in intermediaterisk acute myeloid leukemia patients

    Oncotarget, Vol. 8, Núm. 44, pp. 76003-76014

2016

  1. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico

    Biology of Blood and Marrow Transplantation, Vol. 22, Núm. 3, pp. 584-588

2015

  1. CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

    Haematologica

  2. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival

    Journal of Pathology, Vol. 235, Núm. 3, pp. 445-455

  3. Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML

    American Journal of Clinical Pathology, Vol. 144, Núm. 3, pp. 484-492

  4. GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT

    Bone Marrow Transplantation, Vol. 50, Núm. 1, pp. 121-126

2013

  1. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate

    Haematologica, Vol. 98, Núm. 4, pp. 526-532

2012

  1. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/ Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

    Haematologica, Vol. 97, Núm. 2, pp. 310-317

  2. Evaluation of prognostic factors among patients with chronic graft-versus-host disease

    Haematologica, Vol. 97, Núm. 8, pp. 1187-1195

2011

  1. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

    Haematologica, Vol. 96, Núm. 10, pp. 1448-1456

2010

  1. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: Long-term follow-up from two prospective multicenter trials

    Haematologica, Vol. 95, Núm. 7, pp. 1176-1182

  2. Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source

    Biology of Blood and Marrow Transplantation, Vol. 16, Núm. 7, pp. 957-966

2008

  1. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival

    Journal of Clinical Oncology, Vol. 26, Núm. 4, pp. 577-584

  2. The Effect of In Vivo T Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia

    Biology of Blood and Marrow Transplantation, Vol. 14, Núm. 11, pp. 1288-1297

2007

  1. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: Impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes

    British Journal of Haematology, Vol. 139, Núm. 1, pp. 70-80